Targeting both core spliceosomal components in MYC-dependent breast cancer (Hsu et al., 2015) and snRNP assembly through PRMT5 in MYC-driven lymphoma (Koh et al., 2015) impaired tumourigenicity and implied a therapeutic vulnerability in cancers reliant on oncogenic MYC (Fig. 4). This evidence concerns the gene MYC and lymphoma.